Mednet Logo
CommunityMedical Oncology

What is your preferred approach to metastatic PDL1 negative TNBC?

Does the results of the tnAcity trial influence your decision in choosing a 1st line option?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Brigham and Women's Hospital and Dana-Farber Cancer Institute
Answered on

I usually treat mTNBC (that are PL-D1 negative and BRCAwt) with single agent chemotherapy in the first line setting. However, there are some exceptions in which I would consider starting with a chemo doublet. In the setting of young age, good PS, high disease burden, and symptomatic patients with ra...

Join for free or sign in to see the full answer